Articles related to Obstetrics & Gynecology

Blocking expression of FOXK2 in cancer stem cells inhibited growth of these cells, reducing their so-called “stemness,” making them more like normal cells.

Mirvetuximab soravtansine generated an objective response in nearly 1/3 of patients participating. That compares with response rates in the single digits for current treatments in patients whose ovarian cancer doesn’t respond to platinum-based chemotherapy.

This editorial reflects on the work by Lei and colleagues in teasing out hrHPV-negative vs. positive ovarian cancers with a 15-year follow up. But what to do with the knowledge?

The authors summarize the results of the major studies of ICB monotherapy and combinations; review novel combinations under investigation, including ICB with cellular therapies; and discuss potential candidate biomarkers for improving the selection of patients who may respond to ICB.

Clinical trials of a new weight loss medication have found that adults with obesity taking the once-weekly GIP/GLP-1 receptor agonist tirzepatide achieved a mean weight loss of at least 16% at 72 weeks. Most side effects observed were mild to moderate, with the most common being nausea, diarrhea, constipation, and vomiting. The results are considered encouraging.

Primary hyperparathyroidism (PHPT) is associated with increased risk for fractures, cardiovascular disease, kidney disease, and cancer, along with increased mortality. In mild PHPT with modest hypercalcemia and without known morbidities, parathyroidectomy is debated because no long-term randomized trials have been performed related to it.